Kancera

Less than 1K followers

Overview

Investor consensus

All

Webcasts

Press releases

ShowingAll content types

Press release3/31/2026, 6:00 AM

Novakand Pharma to hold Extraordinary General Meeting to decide on future business direction – Comments from the board of directors

Press release3/2/2026, 6:00 AM

Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting

Press release2/25/2026, 3:45 PM

The board evaluates Novakand Pharma’s options after the decision not to execute the planned reverse take over of SVF Vaccines

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release2/12/2026, 4:45 PM

Novakand Pharma applies for Nasdaq’s approval of continued listing of the combined company post a completed reverse takeover with SVF Vaccines

Press release2/6/2026, 7:00 AM

Novakand Pharma enters into share purchase agreement with SVF Vaccines regarding a reverse takeover

Regulatory press release12/22/2025, 7:00 AM

Novakand Pharma enters Letter of Intent with SVF Vaccines regarding a reverse takeover

Regulatory press release11/21/2025, 7:00 AM

Interim Report Third Quarter 2025, July 1 – September 30 Novakand Pharma AB (publ.), org.no. 556806-8851

Press release10/9/2025, 7:00 AM

Novakand Pharma provides an update on the ongoing reverse take over process

Regulatory press release9/23/2025, 1:00 PM

Peter Selin resigns as CEO of Novakand Pharma in mutual agreement with the board

Regulatory press release9/22/2025, 2:00 PM

Kancera AB changes name to Novakand Pharma AB

Regulatory press release9/18/2025, 4:00 PM

Kancera initiates process to seek stakeholders for a reverse take over

Regulatory press release8/28/2025, 6:00 AM

Interim Report First Quarter 2025, April 1 – June 30 Kancera AB (publ.), org.no. 556806-8851

Regulatory press release8/12/2025, 6:00 AM

Kancera terminates letter of intent with Recardio

Press release6/16/2025, 6:30 AM

Kancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145

Regulatory press release6/13/2025, 6:00 AM

Kancera reports positive top-line results from the KANDOVA study

Regulatory press release6/5/2025, 6:00 AM

Kancera reports positive outcome of pre-IND meeting with FDA

Press release5/27/2025, 6:39 AM

Redeye: Kancera Q1 - Continued efforts with Recardio

Regulatory press release5/23/2025, 6:00 AM

Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

Press release5/20/2025, 6:30 AM

Kancera provides an update on the collaboration with Recardio Inc. and the company’s clinical development program

Press release4/8/2025, 6:00 AM

Kancera reports Last Patient Last Visit in the KANDOVA study

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.